Apellis Pharmaceuticals Announces The Lancet Publishes 24-Month Results From Phase 3 Studies Of SYFOVRE For Geographic Atrophy
Portfolio Pulse from Benzinga Newsdesk
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced that The Lancet published positive 24-month results from Phase 3 studies of SYFOVRE for geographic atrophy (GA). SYFOVRE demonstrated clinically meaningful reductions in GA lesion growth and is the only treatment approved for use beyond 12 months for GA. The company has five additional applications under review globally.
October 20, 2023 | 12:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Apellis Pharmaceuticals' SYFOVRE has shown positive results in Phase 3 studies for GA, with the results published in The Lancet. The drug is the only approved treatment for use beyond 12 months for GA, potentially giving it a competitive edge in the market.
The positive results from the Phase 3 studies of SYFOVRE and its approval for use beyond 12 months for GA could potentially increase the demand for the drug, leading to increased revenues for Apellis Pharmaceuticals. This could have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100